ardelyx
The Vice President, Clinical Development at Ardelyx will lead and execute clinical development strategies for current and future pipeline programs, with a focus on pediatric gastroenterology initiatives. Reporting to the Chief Medical Officer, this role involves cross‑functional collaboration, regulatory interactions, and the opportunity to build and mentor a growing clinical development organization.
Headquarters
Waltham, Massachusetts, United States
Company Size
201-500 employees
Founded
2007
Ardelyx is a biopharmaceutical company that discovers, develops, and commercializes first-in-class medicines for patients with unmet medical needs in gastrointestinal and cardiorenal diseases. The company markets IBSRELA (tenapanor) for irritable bowel syndrome with constipation (IBS-C) and XPHOZAH for chronic kidney disease with hyperphosphatemia, while also pursuing additional pipeline programs including chronic idiopathic constipation. Headquartered in Northern California, Ardelyx is committed to delivering novel-mechanism therapies that improve outcomes for patients with GI and kidney disorders.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for ardelyx.
Vice President, Translational Medicine & Clinical Pharmacology
Rigel Pharmaceuticals
Vice President of Translational Medicine
Flagship Pioneering, Inc.
Vice President (VP), Clinical Development - Infectious Disease
Tonix Pharmaceuticals
Physician Leader, Clinical Development
ImmunEdge, Inc
Vice President, Clinical Development Program Leader
Madrigal Pharmaceuticals
Vice President, Clinical Development Program Leader (MD)
Madrigal Pharmaceuticals